DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

If you are wondering whether DexCom at around US$64 a share looks appealing or expensive, this article breaks down what that price might actually represent for you. The stock has been under pressure ...

DexCom’s fair value price target has been tweaked from US$85.85 to US$86.12 per share, a small shift that still matters if ...

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Without a specific news headline driving the move, DexCom (DXCM) sits at a recent close of ...

When our senior convertible notes are dilutive on a GAAP or non-GAAP basis, net income used for calculating GAAP and non-GAAP diluted net income per share includes an interest expense add back, net of ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

DexCom reported mixed Q2 results with an earnings beat, but revenue missed expectations. The company lowered its full-year revenue guidance. DexCom's steep valuation is only justifiable with sustained ...